Sfoglia per Autore
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.
1992 Dalla Volta, S; Palla, A; Santolicandro, A; Giuntini, C; Pengo, V; Visioli, O; Zonzin, P; Zanuttini, D; Barbaresi, F; Agnelli, Giancarlo
Fibrin clots obtained from plasma containing heparin show a higher sensitivity to t-PA-induced lysis.
1992 Nenci, Gg; Parise, P; Morini, M; Rossini, A; Agnelli, Giancarlo
Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits.
1992 Agnelli, Giancarlo; Pascucci, C; Colucci, M; Nenci, Gg; Mele, A; Bürgi, R; Heim, J.
[Spinal anesthesia and prophylaxis of venous thromboembolism. Results of a national survey].
1992 Pasqualucci, V; Falconi, S; Chianella, A; Firmi, L; Agnelli, Giancarlo
New strategies for enhancing the speed and rate of coronary reperfusion.
1993 Agnelli, Giancarlo
Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
1993 Agnelli, Giancarlo; Pascucci, C; Nenci, Gg; Mele, A; Bürgi, R; Heim, J.
The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
1993 Cosmi, B; Agnelli, Giancarlo; Young, E; Hirsh, J; Weitz, J.
Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
1993 Parise, P; Morini, M; Agnelli, Giancarlo; Ascani, A; Nenci, Gg
Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
1993 Colucci, M; Cavallo, Lg; Agnelli, Giancarlo; Mele, A; Bürgi, R; Heim, J; Semeraro, N.
A hybrid plasminogen activator binds to the u-PA receptor and has a reduced thrombolytic potency in vivo.
1993 Asselbergs, Fa; Bürgi, R; Hamerman, J; Heim, J; van Oostrum, J; Agnelli, Giancarlo
Intramuscular dermatan sulfate MF701 in patients with hip fracture: relationship between pharmacokinetics and antithrombotic efficacy.
1994 Imbimbo, Bp; Sié, P; Agnelli, Giancarlo; Saivin, S; Dupouy, D; Damiani, M; Houin, G; Gianese, F.
Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.
1994 Goldhaber, Sz; Agnelli, Giancarlo; Levine, Mn
Plasma thrombin neutralization assay: pharmacokinetic applications.
1994 Iorio, Alfonso; Alatri, A; Mazzolai, L; Agnelli, Giancarlo
Treatment of venous thromboembolism: unfractionated heparin or low molecular weight heparins?
1995 Agnelli, Giancarlo
Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives.
1995 Agnelli, Giancarlo
Clinical outcome of orthopaedic patients with negative lower limb venography at discharge.
1995 Agnelli, Giancarlo; Ranucci, V; Veschi, F; Rinonapoli, E; Lupattelli, Luciano; Nenci, Gg
Diagnosis of deep vein thrombosis in asymptomatic high-risk patients.
1995 Agnelli, Giancarlo; Radicchia, S; Nenci, Gg
Effects of desmopressin on hemostasis in patients with liver cirrhosis.
1995 Agnelli, Giancarlo; Parise, P; Levi, M; Cosmi, B; Nenci, Gg
[Current applications and perspectives of thrombolytic therapy in peripheral arterial diseases and deep venous thrombosis].
1995 Agnelli, Giancarlo
Distribution and occlusiveness of thrombi in patients with surveillance detected deep vein thrombosis after hip surgery.
1996 Ascani, A; Radicchia, S; Parise, P; Nenci, Gg; Agnelli, Giancarlo
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile